<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461537</url>
  </required_header>
  <id_info>
    <org_study_id>DKMS-14-01</org_study_id>
    <secondary_id>2014-003124-44</secondary_id>
    <nct_id>NCT02461537</nct_id>
  </id_info>
  <brief_title>Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML</brief_title>
  <acronym>ETAL3-ASAP</acronym>
  <official_title>Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DKMS gemeinnützige GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DKMS gemeinnützige GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial compares outcome of two treatment strategies for patients with high-risk AML who&#xD;
      failed to achieve or maintain a complete remission with standard therapy. Patients will be&#xD;
      randomized between two strategies. The standard strategy is aimed at achieving a complete&#xD;
      remission by aggressive salvage chemotherapy using high dose cytarabine and mitoxantrone, .&#xD;
      The alternative is a less toxic disease-control strategy of disease monitoring and, if&#xD;
      necessary, low-dose cytarabine or mitoxantrone prior to allogeneic transplantation, which&#xD;
      should be performed as soon as possible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with high-risk acute myeloid leukemia (AML) who relapsed or showed a poor response&#xD;
      to induction chemotherapy have a dismal prognosis. For these patients, allogeneic&#xD;
      transplantation is the recommended treatment. While allogeneic transplantation may be&#xD;
      considered as the ultimate treatment concept, the treatment path to transplantation is not&#xD;
      well defined.&#xD;
&#xD;
      The traditional approach to pursue a complete remission by means of aggressive reinduction&#xD;
      chemotherapy prior to allogeneic transplantation. This approach is associated with&#xD;
      potentially life-threatening toxicities and has limited efficacy. As a result, only some&#xD;
      patients will reach allogeneic transplantation in complete remission.&#xD;
&#xD;
      To reduce the number of patients who die or who are ineligible for transplantation due to the&#xD;
      toxicity of aggressive induction chemotherapy, other bridging options have been explored. One&#xD;
      promising alternative is to abstain from remission induction. Instead, disease control by&#xD;
      means of less aggressive chemotherapy or simply monitoring leukemic proliferation can be&#xD;
      considered.&#xD;
&#xD;
      This randomized trial will identify if there is non-inferiority of the less toxic approach,&#xD;
      compared to the standard approach of remission induction by aggressive chemotherapy prior to&#xD;
      allogeneic transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>on day 56 after allogeneic SCT</time_frame>
    <description>Disease-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 weeks, 8 weeks, and 24 weeks from randomization</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of allogeneic transplantation</measure>
    <time_frame>4 weeks, 8 weeks, and 16 weeks from randomization</time_frame>
    <description>Rate of allogeneic transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CR</measure>
    <time_frame>at 4 weeks, 8 weeks, and 24 weeks from randomization</time_frame>
    <description>Incidence of CR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>RIST(remission induction)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DISC (disease control)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAM</intervention_name>
    <description>High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)</description>
    <arm_group_label>RIST(remission induction)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDAC and/or Mitoxantrone</intervention_name>
    <description>Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)</description>
    <arm_group_label>DISC (disease control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Male and female patients of 18 to 75 years of age.&#xD;
&#xD;
          -  Diagnosis of AML according to WHO criteria.&#xD;
&#xD;
          -  Patient is fit for aggressive induction chemotherapy and transplantation by assessment&#xD;
             of an experienced hematologist.&#xD;
&#xD;
          -  No history of chronic pulmonary disease and absence of dyspnea. Otherwise, documented&#xD;
             diffusion lung capacity for carbon monoxide ( DLCO ) ≤ 40 percent ( adjusted for&#xD;
             hemoglobin, if available ) and FEV1 / FVC ≥ 50 percent.&#xD;
&#xD;
          -  HLA - identical sibling. or&#xD;
&#xD;
          -  HLA - compatible unrelated donor ( ≥ 9 /10 antigens matched for HLA - A, - B, - C,&#xD;
             -DRB 1, and - DQB 1 ) with completed confirmatory typing or&#xD;
&#xD;
          -  Two unrelated donors with &gt; 90 percent probability of a 9 /10 match for HLA - A, - B,&#xD;
             - C, - DRB 1, and - DRQB 1, according to Opti Match ® list.&#xD;
&#xD;
        For the relapse stratum&#xD;
&#xD;
          -  First AML relapse, defined as ≥ 5 percent bone marrow blasts and / or extramedullary&#xD;
             AML manifestation.&#xD;
&#xD;
        For the poor - responders stratum&#xD;
&#xD;
          -  AML that evolves from previously documented myelodysplastic syndrome ( MDS ),&#xD;
&#xD;
        and / or&#xD;
&#xD;
          -  diagnosis of therapy-related myeloid neoplasm ( t - MN ), and / or&#xD;
&#xD;
        a ) If patient ≤ 60 years old adverse risk AML according to ELN - criteria and ≥ 5 percent&#xD;
        bone marrow blasts after the first cycle of induction therapy.&#xD;
&#xD;
        b ) If patient &gt; 60 years old non-favourable risk AML according to ELN - criteria and ≥ 5&#xD;
        percent bone marrow blasts after the first cycle of induction therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Acute promyelocytic leukemia ( APL ).&#xD;
&#xD;
          -  WBC count of ≥ 50 GPt / L at study inclusion.&#xD;
&#xD;
          -  For patients in the poor - responder stratum the first cycle of induction therapy must&#xD;
             not contain HDAC, defined as cytarabine at single-doses of &gt; 1 g / m 2.&#xD;
&#xD;
          -  Patient has received more than 440 mg / m2 daunorubicin equivalents.&#xD;
&#xD;
          -  Severe organ dysfunction, defined as&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50 percent.&#xD;
&#xD;
          -  Patients who receive supplementary continuous oxygen.&#xD;
&#xD;
          -  Serum bilirubin &gt; 1.5 x ULN ( if not considered Gilbert-Syndrome ), ASAT / ALAT &gt; 5 x&#xD;
             ULN.&#xD;
&#xD;
          -  Estimated GFR &lt; 50 ml / min.&#xD;
&#xD;
          -  Treatment with any investigational drug within 10 days before study entry.&#xD;
&#xD;
          -  Uncontrolled infection at the time of enrollment.&#xD;
&#xD;
          -  History of allogeneic transplantation.&#xD;
&#xD;
          -  Manifestation of AML in the central nervous system.&#xD;
&#xD;
          -  Pregnant or breast - feeding women.&#xD;
&#xD;
          -  Men unable or unwilling to use adequate contraception methods from start of study&#xD;
             treatment to minimum of six months after the last dose of chemotherapy.&#xD;
&#xD;
          -  Women of childbearing potential except those who fulfill the following criteria:&#xD;
             Post-menopausal or post-operative or continuous and correct application of a&#xD;
             contraception method with a Pearl Index &lt; 1 percent or sexual abstinence or vasectomy&#xD;
             of the sexual partner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Schetelig, Prof Dr med</last_name>
    <role>Study Chair</role>
    <affiliation>Universtitätsklinikum Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Trost, MSc</last_name>
    <phone>+49351210798</phone>
    <phone_ext>28</phone_ext>
    <email>strost@dkms.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Dreger, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan A. Klein, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Kaufmann, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfgang Bethge, Prof Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Kliniken gGmbH</name>
      <address>
        <city>Winnenden</city>
        <state>Baden-Württemberg</state>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Markus Schaich, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Bavaria</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Schmid, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Krause, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <state>Bavaria</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kerstin Schäfer-Eckart, Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60595</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gesine Bug, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, AÖR</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westphalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edgar Jost, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR)</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westphalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Noppeney, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Stelljes, Prof Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Wagner-Drouet, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <state>Saxony-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lutz Peter Müller, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Schetelig, Prof Dr med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg-Nikolaus Franke, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elblandkliniken Stiftung &amp; Co. KG</name>
      <address>
        <city>Riesa</city>
        <state>Saxony</state>
        <zip>01589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jörg Schubert, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Judith Niederland, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

